Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Styers, David ^a   Sheehan, Daniel J ^b   Hogan, Patricia ^b   Sahm, Daniel F ^a  

^a Focus Bio Inova Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; OUTPATIENT; PHENOTYPE; PREVALENCE; SPECIES DIFFERENCE; STAPHYLOCOCCUS INFECTION; UNITED STATES; DRUG EFFECT; LABORATORY; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LABORATORIES; METHICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 33644923830     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-2     Document Type: Article

References (26)

1. Deresinski S: Methicillin-resistant Staphylococcus oureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005, 40:562-573.
2. Chambers HF: The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001, 7:178-82.
3. Sahm DF, Marsilio MK, Piazza G: Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database - USA. Clin Infect Dis 1999, 29:259-63.
4. Jones ME, Mayfield DC, Thornsberry C, Karlowsky JA, Sahm DF, Peterson D: Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother 2002, 46:3104-5.
5. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginoso and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003, 47:1681-88.
6. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF: Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004, 48:2431-6.
7. Fridkin SK, Edwards JR, Tenover FC, et al.: Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001, 33:324-30.
8. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, Karlowsky JA: Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated In the United States in 2000-2001. Antimicrob Agents Chemother 2003, 47:1689-1693.
9. Diekema DJ, Pfaller MA, Schmitz FJ, et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl 2):S114-S132.
10. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999, 29:239-44.
11. Fridkin SK, Steward CD, Edwards JR, et al.: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999, 29:245-52.
12. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June issued August 2003. Am J Infect Control 2003, 31:481-98.
13. Eguia JM, Chambers HE Community-acquired methicillin resistant Staphylococcus aureus: epidemiology and potential virulence factors. Curr Infect Dis Reports 2003, 5:459-66.
14. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS: Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003, 37:1050-58.
15. Naimi TS, LeDell KH, Como-Sabetti K, et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-84.
16. Said-Salim B, Mathema B, Kreiswirth BN: Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003, 24:451-55.
17. Stemper ME, Shukla SK, Reed KD: Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin, 1989 to 1999. J Clin Microbial 2004, 42:5673-80.
18. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al.: Origins of community strains of methicillin-resistant Stophylococcus aureus. Clin Infect Dis 2004, 39:47-54.
19. Tacconelli E, Venkataraman L, De Girolami PC, D'Agata EM: Methicillin-resistant Staphylococcus aureus bacteraemia. diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 2004, 53:474-9.
20. Francis JS, Doherty MC, Lopatin U, et al.: Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panoton-Valentine leuckocidin genes. Clin Infect Dis 2005, 40:100-107.
21. Lina G, Piemont Y, Godail-Gamot F, et al.: Involvement of Panton-Valentine Leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-32.
22. Vandenesch F, Naimi T, Enright MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine Leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-84.
23. Meka VG, Gold HS: Antimicrobial resistance to linezolid. Clin Infect Dis 2004, 39: 1010-15.
24. Stevens DL, Herr D, Lampiris H, et al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-90.
25. Wargo KA, Eiland EH: Appropriate antimicrobial therapy for community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine Leukocidin genes. Clin Infect Dis 2005, 40:1376-8.
26. Wilcox M, Nathwani D, Dryden M: Linezolid compared with teicoplanin for the treatment of suspected or proven grampositive infections. J Antimicrob Chemother 2004, 53:335-44.